

Center for Vaccine
Ethics and Policy



Vaccines and Global Health: The Week in Review
29 June 2024 :: Issue 757
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



[The Sustainable Development Goals Report - 2024](#)

United Nations DESA – *in collaboration with the entire UN Statistical System, consisting of more than 50 international and regional agencies, based on data from over 200 countries and territories.*

28 June 2024


PDF: <https://unstats.un.org/sdgs/report/2024/The-Sustainable-Development-Goals-Report-2024.pdf>

The Sustainable Development Goals Report 2024 details the significant challenges the world is facing in making substantial strides towards achieving the SDGs based on the latest data and estimates. It features areas with setbacks while also showcasing where tangible progress has been made, for instance, in reducing global child mortality, preventing HIV infection, and access to energy and mobile broadband. The report also highlights where action must accelerate, particularly in critical areas undermining SDG progress - climate change, peace and security, inequalities among and between countries, among others.

According to the report, with just six years remaining, current progress falls far short of what is required to meet the SDGs. Without massive investment and scaled up action, the achievement of the SDGs — the blueprint for a more resilient and prosperous world and the roadmap out of current global crises — will remain elusive.

The lingering impacts of the COVID-19 pandemic, escalating conflicts, geopolitical tensions and growing climate chaos have severely hindered progress. The report details the urgent priorities and areas needed for stronger and more effective action to ensure the 2030 promise to end poverty, protect the planet and leave no one behind.

Progress assessment for the 17 Goals based on assessed targets, by Goal (percentage)





Good health and well-being

- The COVID-19 pandemic has ravaged global health, undoing nearly 10 years of progress in life expectancy. While most health-related indicators are moving in the right direction globally, current trends are insufficient to meet targets set for 2030.
- The maternal mortality ratio is largely stuck at a level more than three times the 2030 target. Under-5 deaths reached an historic low in 2022, but progress has slowed. Without accelerated declines, 35 million children will not live to see their fifth birthday by 2030.
- The global response to infectious diseases has saved millions of lives and paved the way for healthier communities. Inequalities and emerging threats jeopardize these accomplishments, however, underscoring the need for sustained efforts and innovative strategies.
- More than half the world's population is not covered by essential health services, while an ageing health workforce must now meet growing demands from an ageing population. Ensuring universal health coverage without financial hardship is crucial to healthy lives and well-being for all.



A child receives an oral polio vaccine during the launch of a nationwide polio campaign in Malawi.

- The world is not on track to achieve Goal 3. Changing course requires prioritizing the achievement of universal health coverage, strengthening health systems, investing in disease prevention and treatment, and addressing disparities in access to care and services, especially for vulnerable populations.

[p.15]

Twenty-one million children missed out on life-saving vaccines in 2022

Between 2000 and 2019, the proportion of children receiving three doses of the diphtheria, tetanus and pertussis (DTP3) vaccine rose from 72 to 86 per cent, then dipped to 81 per cent in 2021 before rebounding to 84 per cent in 2022. In 2022, 20.5 million children missed at least one routine vaccine and 14.3 million received no vaccines at all. Coverage of two doses of the measles vaccine and three doses of the pneumococcal conjugate vaccine increased in 2022, reaching 74 per cent and 60 per cent, respectively, following stagnation in 2020–2021. Global coverage of the human papillomavirus (HPV) vaccine, critical for women's and girls' health, stood at only 15 per cent in 2022, despite 130 countries introducing it in their national immunization services by the end of the year.

Foreword

The Sustainable Development Goals Report 2024 makes for sobering reading.

It finds that **only 17 per cent of the SDG targets are on track, nearly half are showing minimal or moderate progress, and progress on over one third has stalled or even regressed.** The scarring effects of the COVID-19 pandemic, escalating conflicts, geopolitical tensions, and growing climate chaos are hitting SDG progress hard.

Furthermore, **systemic deficiencies and inequities in the global economic and financial system leave developing countries to tackle enormous and growing challenges** with only a fraction of the international support they need and deserve.

Inequalities keep growing. The climate crisis continues to escalate. Biodiversity loss is accelerating. Progress towards gender equality remains disappointing. And conflicts in Ukraine, Gaza, Sudan and beyond have left an unprecedented 120 million forcibly displaced people worldwide.

This situation is not going to improve on its own: developing countries, as a whole, face the worst medium-term economic outlook in a generation.

Against this backdrop, the steadfast unity of governments behind the 2030 Agenda, as demonstrated at the SDG Summit in September 2023, offers a glimmer of hope. Their commitment to rescue the SDGs and to deliver an SDG Stimulus has generated fresh impetus behind the Goals.

This report also highlights that despite deeply worrying trends, progress is being made – with reductions in child mortality, HIV infections, and the cost of remittances and improvements in access to water, sanitation, energy, and mobile broadband.

To turn these green shoots into accelerated and transformative progress, **bolder actions are required:**

First, we need peace.

We must resolve ongoing armed conflicts through dialogue and diplomacy, and prevent future conflicts by upholding the principles and values of the Charter of the United Nations.

Second, we need solidarity.

Developing countries urgently require more financial resources and fiscal space. We must reform the outdated, dysfunctional and unfair international financial architecture to facilitate far greater investment in the SDGs.

Third, we need a surge in implementation.

Massive investment and more effective partnerships are needed to drive critical transitions across food, energy, digital connectivity and more, unlocking progress right across the Goals.

And underpinning all our efforts must be a more concerted effort to dismantle gender barriers and empower all women and girls – because we cannot expect to achieve the Goals without gender equality.

This report highlights the **urgent need for stronger and more effective international cooperation to maximize progress starting now.** This year's Summit of the Future provides a vital opportunity, paving the way for further breakthroughs at the Financing for Development conference and World Social Summit in 2025.

With more than six years left, we must not let up on our 2030 promise to end poverty, protect the planet and leave no one behind.

António Guterres Secretary-General of the United Nations

.....
.....

Featured Journal Content

PNAS - Proceedings of the National Academy of Sciences of the United States

June 25, 2024 vol. 121 no. 26

<https://www.pnas.org/toc/pnas/121/25>

[The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic](#)

In response to the COVID-19 pandemic, governments directly funded vaccine research and development (R&D), quickly leading to multiple effective vaccines and resulting in enormous health and economic benefits to society. We develop a simple economic model ...

Daniel Tortorice, Rino Rappuoli and David E. Bloom

Significance

The COVID-19 pandemic showed that a public research and development (R&D), push can accelerate discovery, yielding enormous health and economic benefits. To explore whether this feat could be repeated, we develop a model of R&D and apply it to Streptococcus A and Alzheimer's disease. We find spending US\$34 billion is optimal to develop vaccines against Streptococcus A. This spending is expected to generate US\$2 trillion in benefits, corresponding to a return on investment of 23% per year for 30 y. For Alzheimer's disease, we find optimal spending of US\$5.7 trillion. The corresponding benefits are US\$61 trillion with a return of 12.1%. We discuss policies to increase health R&D spending with the potential to unlock these massive global health benefits.

Abstract

In response to the COVID-19 pandemic, governments directly funded vaccine research and development (R&D), quickly leading to multiple effective vaccines and resulting in enormous health and economic benefits to society. We develop a simple economic model showing this feat could potentially be repeated for other health challenges. Based on inputs from the economic and medical literatures, the model yields estimates of optimal R&D spending on treatments and vaccines for known diseases. Taking a global and societal perspective, we estimate the social benefits of such spending and a corresponding rate of return. Applications to Streptococcus A vaccines and Alzheimer's disease treatments demonstrate the potential of enhanced research and development funding to unlock massive global health and health-related benefits. We estimate that these benefits range from 2 to 60 trillion (2020 US\$) and that the corresponding rates of return on R&D spending range from 12% to 23% per year for 30 y. We discuss the current shortfall in R&D spending and public policies that can move current funding closer to the optimal level.

.....
.....

[CDRH Announces Partnership to Develop New Methods to Accelerate Diagnostic Device Development for Underserved Populations – FDA](#)

June 26, 2024

Today, the FDA's Center for Devices and Radiological Health (CDRH) is announcing a partnership with the Bill and Melinda Gates Foundation to create **new analytical methods to help the development of breath-based diagnostic devices for disease detection in underserved populations.**

In particular, these methods are intended to identify multiple chemicals or biomarkers in complex chemical mixtures, and thereby increase the potential for chemical characterization to identify multiple chemicals when used in premarket device testing.

Due to high costs and the complexity of the instruments needed to perform an analysis, **disease detection in remote and impoverished areas can be extremely challenging. These new methods are intended to help developers create a more efficient and affordable option that could be more easily deployed across populations living in rural and remote areas.**

To ensure confidence in our measurement techniques, this project will include developing, curating, and validating an interactive web database of both healthy breath and breath infected with Mycobacterium tuberculosis bacteria (TB). Using spectral criteria and a scoring system based on robust analytical chemistry methods, the web database can then be used by innovators and researchers to assist in identifying important diagnostic biomarkers for TB patients.

This full characterization and establishment of a basal-level breath-print will give the diagnostics community the ability to confidently identify disease biomarkers and facilitate the development of next-generation diagnostic devices that can be used by clinicians and consumers at the point of care and in the home...

With the support of a \$1.9 million grant from the Bill and Melinda Gates Foundation, the goal of this collaboration will ultimately be the development of a pathway for identification and an opportunity for treatment of disease in rural and medically underserved areas.

The FDA will work toward this goal, in collaboration with the National Institute of Standards and Technology (NIST), which is also partnering with the Bill and Melinda Gates Foundation...

.....
.....

MSF strengthening commitment to access to products for healthcare

Access to medicines

Press Release 25 Jun 2024

Driven by a new collective vision to expand our efforts to improve access to products for healthcare for people in greatest need, Médecins Sans Frontières **(MSF) is implementing a new structure that will replace the MSF Access Campaign** and build on its remarkable achievements.

"As we undergo this transition, we continue our work and commitment to getting medicines and urgent healthcare products to the people and communities who are often denied access to them," says Dr. Christos Christou, MSF international president.

People face unacceptable levels of suffering because of a lack of access to products for healthcare, in places where MSF works and beyond. Being able to access and afford the right products - vital medical tools - for healthcare is essential to MSF's ability to provide quality medical assistance to people who need it most.

MSF has a long history of innovation and developing adapted products for communities facing crisis as well as in challenging unfair practices affecting the availability and pricing of drugs, diagnostics and vaccines.

Since its launch in 1999, the Access Campaign has fought to tear down structural barriers that prevent medical teams and patients from accessing healthcare products needed to save lives. The work is a critical part of the implementation of the organisation's social mission.

"Over the coming decade, MSF will redouble its efforts to deliver tangible improvements in access to products for healthcare, proudly building on the exceptional work that the Access Campaign has done for the last 25 years," says Dr. Christos Christou, MSF international president.

The new structure will be closer to our medical humanitarian operations, to better support the needs of the communities we assist. Five regional offices (in Kuala Lumpur, Malaysia; Nairobi, Kenya; Dakar, Senegal; Rio de Janeiro, Brazil; and Brussels, Belgium) will work together with our operational teams and patients as well as with our partners and networks. A dedicated internal fund will also be set up to support access-related initiatives throughout the organisation.

MSF's focus is on directly addressing the problems our patients and our operational teams face. MSF will also continue to work globally to address systemic barriers causing or amplifying these problems. This includes advocating for changes to policy and practices that determine who can or cannot access lifesaving healthcare products in many of the more than 70 countries around the world where MSF works.

These changes and evolution are the result of over two years of in-depth consultations with hundreds of MSF staff. This new structure is expected to be operational from January 2025 and will initially focus on continuing key work currently run by the Access Campaign.

MSF remains committed to improving the accessibility, availability, affordability, appropriateness and quality of products for healthcare for the patients and communities we assist.

.....

[In an open letter, Unitaïd urges MSF to continue its critical work in advancing access for key health products](#)

27 June 2024

In an open letter to the international president of Médecins Sans Frontières (MSF), Unitaïd urges MSF to continue its critical work to advance access to health technologies. Unitaïd's letter follows news that MSF plans to shut down the Access Campaign, an international advocacy project that works to increase access to essential health products, by the end of 2024...

.....

.....

.....

Polio – PHEIC

[Polio this week as of 26 June 2024 - GPEI](#)

Summary of new polioviruses this week, cases and positive environmental isolates:

- :: Pakistan: ten WPV1-positive environmental samples
- :: Ethiopia: one cVDPV2 case
- :: Madagascar : two cVDPV1-positive environmental samples
- :: South Sudan: one cVDPV2-positive environmental sample
- :: Yemen: five cVDPV2 cases

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)
:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 29 June 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

No new digest content identified.

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: [Rallying action to curb cholera in Nigeria's Lagos state](#)

27 June 2024

WHO Region of the Americas PAHO

:: [PAHO 174th session of the Executive Committee concludes with approval of resolutions to strengthen health in the Americas](#)

Washington, D.C., June 28, 2024 (PAHO) - The 174th session of the Executive Committee of the Pan American Health Organization (PAHO) concluded yesterday after four days of deliberations, where representatives of the nine Member States that make up this governing body, and observers, addressed a critical agenda for public health in the region...

:: [New PAHO report shows NCDs continue as main cause of death and disability in the Americas, warns countries to prepare health systems for rapidly aging population](#)

Washington D.C. 28 June 2024 – A new report launched by the Pan American Health Organization (PAHO) reveals that while overall life expectancy has risen in the Americas, so has the number of people living with noncommunicable diseases (NCDs). Rapid population aging has led to an increase in ill health and disabilities caused by noncommunicable...

:: [Nearly 1.8 billion adults at risk of disease from not doing enough physical activity](#)

26 June 2024 | Geneva — New data show that nearly one third (31%) of adults worldwide, approximately 1.8 billion people, did not meet the recommended levels of physical activity in 2022. The findings point to a worrying trend of physical inactivity among adults, which has increased by about 5 percentage points between 2010 and 2022.If the...

:: [Over 3 million annual deaths due to alcohol and drug use, majority among men](#)

25 June 2024 — A new report from the World Health Organization (WHO) highlights that 2.6 million deaths per year were attributable to alcohol consumption, accounting for 4.7% of all deaths, and 0.6 million deaths to psychoactive drug use. Notably, 2 million of alcohol and 0.4 million of drug-attributable deaths were among men.WHO's ...

:: [PAHO Executive Committee opens to discuss priority issues, including epidemic intelligence and health sector action on climate change](#)

Washington, D.C., June 24, 2024 (PAHO) - The Executive Committee of the Pan American Health Organization (PAHO) today began its 174th session in Washington, D.C., addressing more than 40 crucial issues to improve health in the Americas. Topics of discussion will include strengthening the health sector in the face of climate change, and...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 25 June 2024 News release

[Building evidence for the use of bacteriophages against antimicrobial resistance](#)

:: 25 June 2024 Departmental update

[Building a preparedness leadership workforce: a WHO Collaborating Centre guides the way](#)

:: 24 June 2024 Statement

[Statement – We are a long way from ending TB in the European Region, but there is hope on the horizon](#)

:: 24 June 2024 Media release

[Securing our TB-free future: eastern European and central Asian health leaders increase political commitment to ending TB](#)

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations.

[Multi-country outbreak of mpox, External situation report#34- 28 June 2024](#)

[WHO's Operational Update on Health Emergencies - May 2024](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 26, pp. 339–350 28 June 2024

PDF: <https://iris.who.int/bitstream/handle/10665/378072/WER9926-eng-fre.pdf>

:: 339 Index of countries/areas

:: 339 Index, Volume 99, 2024, Nos. 1–26

:: 342 Persistent transmission of circulating vaccine-derived poliovirus – Somalia, January 2017–March 2024

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

27 June 2024

[Antimicrobial Resistance Diagnostic Initiative](#)

26 June 2024

[Handbook for conducting assessments of barriers to effective coverage with health services](#)

26 June 2024

[Target product profile for a diagnostic test to confirm cure of visceral leishmaniasis](#)

25 June 2024

[Enhancing compliance to good manufacturing practices and pharmaceutical quality system requirements in...](#)

24 June 2024

[Refugee and migrant health system review: challenges and opportunities for long-term health system strengthening in Jordan](#)

24 June 2024

[Mekong malaria elimination: epidemiology summary, volume 24, October–December 2023](#)

24 June 2024

[Report of the first meeting of the Global Onchocerciasis Network for Elimination: Saly, Senegal, 1-2...](#)

24 June 2024

[Translating global and regional political commitments towards ending TB into action in the South-East...](#)

.....

.....

USA – HHS, FDA, CDC

HHS

News

No new digest content identified.

FDA

Press Announcements

[FDA Roundup: June 28, 2024](#)

... On Wednesday, **the FDA announced a partnership with the Bill and Melinda Gates Foundation to create new analytical methods to help the development of breath-based diagnostic devices for infectious disease detection in underserved populations**, thereby promoting and fostering health equity. "Guided by our shared interest in advancing health equity and equality, this partnership can ultimately open the possibility of widespread disease detection in medically underserved populations both domestically and globally," said CDRH Director Jeff Shuren,

M.D., J.D., and CDRH's Office of Science and Engineering Laboratories (OSEL) Director Ed Margerrison, Ph.D. The methods will include a database of chemical information, criteria for classifying confidence of a chemical identification and a web application for analysis of mass spectrometry data. These methods are intended to help drive confidence in measurement techniques and ultimately reduce risk for developers, medical device innovators and regulators.

[June 26, 2024 - FDA Guidance Provides New Details on Diversity Action Plans Required for Certain Clinical Studies](#)

Today, the U.S. Food and Drug Administration issued a [draft guidance](#), "*Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies*," to assist medical product sponsors in submitting Diversity Action Plans to support certain clinical studies. Diversity Action Plans are intended to increase clinical study enrollment of participants of historically underrepresented populations to help improve the data the agency receives about the patients who may potentially use the medical product...

FDA VRBPAC

[Advisory Committee Calendar](#)

No meetings appear on calendar.

CDC/ACIP [U.S.] [to 29 June 2024]

<http://www.cdc.gov/media/index.html>

Latest News

[Readout of Advisory Committee on Immunization Practices Meeting Held June 26 – 28, 2024](#)

June 28, 2024 CDC's Advisory Committee on Immunization Practices (ACIP) met June 26 – 28 to discuss data on multiple vaccines. The agenda and presentations are online.

[CDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season](#)

June 27, 2024 Today, CDC recommended the updated 2024-2025 COVID-19 vaccines and the updated 2024-2025 flu vaccines to protect against severe COVID-19 and flu this fall and winter.

[CDC Updates RSV Vaccination Recommendation for Adults](#)

June 26, 2024

[ACIP Meetings](#)

Next ACIP Meeting

[June 26-28 - Draft Agenda](#)

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

June 27, 2024 / No. 25

[PDF of this issue](#)

[:: Persistent Transmission of Circulating Vaccine-Derived Poliovirus — Somalia, January 2017–March 2024](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024

28 June 2024

10 new medicines recommended for approval; another 11 medicines recommended for extension of their therapeutic indications

... mResvia (Respiratory Syncytial Virus (RSV) mRNA vaccine) received a positive opinion from the CHMP for prevention in adults 60 years of age and older of lower respiratory tract disease and acute respiratory disease caused by respiratory syncytial virus, a common respiratory virus that usually causes mild, cold-like symptoms but can lead to serious consequences in older adults. This is the first mRNA vaccine targeting a different pathogen than SARS-CoV-2 that receives a positive opinion from the CHMP...

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

Monthly measles and rubella monitoring report - May 2024

27 Jun 2024

This report provides an overview of measles and rubella cases reported to ECDC through The European Surveillance System (TESSy).

.....
.....

Africa CDC [to 29 June 2024]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

Data curation workshop seeks to strengthen sharing of data on disease-causing pathogens in Africa

22 June 2024

As part of its programme to expand capacity in and support for pathogen genomics around Africa, the Africa Centres for Disease Control and Prevention hosted its first training in data curation, a pillar of modern data science.

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 29 June 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 29 June 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (6)

2024-06-28 / No. 26 **INFECTIOUS DISEASE ISSUE**

[View PDF of this issue](#)

- [Preplanned Studies: The Epidemiological Characteristics of Mpox Cases — China, 2023](#)
- [Preplanned Studies: Protection of Omicron Sub-Lineage Infection Against Reinfection with Another Omicron Sub-Lineage: Systematic Review, Meta-Analysis, and Meta-Regression — Worldwide, 2022–2023](#)
- [Methods and Applications: Exploring the Lagged Correlation Between Baidu Index and Influenza-Like Illness — China, 2014–2019](#)
- [Methods and Applications: Comparison Between Threshold Method and Artificial Intelligence Approaches for Early Warning of Respiratory Infectious Diseases — Weifang City, Shandong Province, China, 2020–2023](#)

Recollection: The COVID-19 Vaccines Evaluation Program: Implementation, Management, and Experiences, 2021–2023

Tingting Yan, et al.

Abstract

In 2021, China's domestically produced coronavirus disease 2019 (COVID-19) vaccines received approval from regulatory bodies and were administered worldwide. Due to a low number of infections within China during that period, it became imperative to evaluate the vaccines' real-world effectiveness through international studies. To facilitate this, China CDC launched the COVID-19 Vaccines Evaluation Program (COVEP). This program formed research collaboration agreements with health institutes across five World Health Organization regions, addressing key questions about vaccine performance through ten cooperative agreements. The findings from COVEP projects reinforced confidence, both domestically and globally, in the effectiveness of the vaccines produced in China. Moreover, the outcomes observed internationally were frequently mirrored by later studies conducted within China. COVEP thus pioneered a novel approach for fostering cross-national research collaborations, addressing significant public health issues and exemplifying a framework for international cooperation. This approach is in line with the strategic objectives and other development efforts of China CDC's national disease control and prevention initiatives.

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Organization Announcements

Paul G. Allen Frontiers Group [to 29 June 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 29 June 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

Press release

Bill Gates Meets With Pakistan Prime Minister, Government Leaders, and Health Workers to Discuss Polio, Health Systems, and Economic Advancement

ISLAMABAD (June 24, 2024) – Bill Gates, co-chair of the Bill & Melinda Gates Foundation, met with Pakistan Prime Minister Shehbaz Sharif, Deputy Prime Minister Ishaq Dar, federal cabinet ministers, provincial ministers of health and chief secretaries and Chief of Army Staff General Asim Munir today to discuss their joint commitments to improving the lives of vulnerable people—especially women and girls—and advancing their shared goals in health, nutrition, climate adaptation, technology, and financial inclusion...

Bill & Melinda Gates Medical Research Institute [to 29 June 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 29 June 2024]

<https://carb-x.org/>

News

06.27.2024 |

CARB-X funds Prompt Diagnostics to develop a diagnostic to detect drug-resistant gonorrhea

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Prompt Diagnostics LLC US\$1 million to further the development of a portable PCR platform with high multiplexing capabilities that, if successful, detect multiple pathogenic bacteria targets and their antibiotic susceptibility which will help to guide treatment at the point-of-care.

CEPI – Coalition for Epidemic Preparedness Innovations [to 29 June 2024]

<http://cepi.net/>

Latest News

Latest experts appointed to join CEPI's Scientific Advisory Committee

24th June 2024

CEPI has appointed eight new experts to its Scientific Advisory Committee (SAC), an external expert group which provides guidance and recommendations to CEPI on R&D programmes and broader

outbreak response efforts.

The new members' scientific input, guidance and challenge will be critical in the continued implementation of the CEPI 2.0 strategy, which aims to accelerate the development of vaccines and other biological countermeasures to tackle emerging infectious diseases and enhance global preparedness for future epidemic and pandemic threats...

The new SAC members are:

Associate Professor Ifedayo Adetifa, Independent Public Health Expert, Nigeria

Dr Paula Goldin, Senior Medical Director PPD, Thermo Fisher, Argentina

Dr Beth-Ann Griswold Collier, Consultant, BCG Vaccine Consulting LLC, USA

Professor Kevin Kee-Jong Hong, Korea mRNA Vaccine Initiative, Korea

Dr Luciana C. C. Leite, Head of Recombinant BCG Laboratory, Instituto Butantan, Brazil,

Dr Placide Mbala-Kingebeni, Head of Epidemiology and Global Health Department, Institut National de Recherche Biomedicale, Democratic Republic of Congo

Mr Sly Ngoni Mutyavaviri, Senior GMP Inspector, Medicines Control Authority of Zimbabwe and SADC Medicines Regulatory Harmonisation Inspections Coordinator, SADC Medicines Regulatory Harmonisation, Zimbabwe

Dr Andre Siqueira, Public Health Researcher, Fundação Oswaldo Cruz (Fiocruz), Brazil

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 29 June 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 29 June 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 29 June 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 29 June 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

Website not responding at inquiry.

Emory Vaccine Center [to 29 June 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 29 June 2024]

<http://www.euvaccine.eu/>

Latest News, Events

No new digest content identified.

Evidence Aid [to 29 June 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

Models and components of risk communication in disasters

Added June 23, 2024

Ethical decision making in disasters and emergencies

Added June 22, 2024

Fondation Merieux [to 29 June 2024]

<http://www.fondation-merieux.org/>

News, Events

Événement co-organisé par la Fondation Mérieux

2ème édition du cours avancé sur l'épidémiologie dans les situations d'urgence complexes

15 - 19 juillet 2024 - Centre des Pensières, Veyrier-du-Lac (France)

Gavi [to 29 June 2024]

<https://www.gavi.org/>

Press Releases

No new digest content identified

GE2P2 Global Foundation [to 29 June 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – June 2024](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 17 June 2024 – Issue 19](#)

GHIT Fund [to 29 June 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 29 June 2024]

<https://www.theglobalfund.org/en/news/>

News & Stories

27 June 2024

Global Fund and Unitaid Increase Collaboration to Advance Equitable Access to Health Products

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and Unitaid signed a new collaboration framework to advance equitable access to high-quality and affordable health products and innovations in low- and middle-income countries ...

26 June 2024

Global Fund to Provide Emergency HIV and TB Prevention Services Amidst Violence in Haiti

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has approved over US\$1.8 million in emergency funding to urgently provide HIV and tuberculosis (TB) prevention services to victims/survivors of gender-based violence (GBV), dis...

24 June 2024

UNAIDS and Global Fund Sign a New Strategic Framework for Their Collaboration to End AIDS

UNAIDS Executive Director, Winnie Byanyima, and Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), Peter Sands, signed a new strategic framework for cooperation and collaboration to end AIDS (2024 –2028)...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 29 June 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 29 June 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 29 June 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 29 June 2024]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [to 29 June 2024]

<https://www.iavi.org/>

News, Features

June 24, 2024

[Advocates push for local manufacturing to achieve health equity in Africa](#)

Research literacy learning collaborative led by CASPR brings together health advocates in Africa, linking the science of vaccine development to vaccine advocacy.

INSERM [to 29 June 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 29 June 2024]

<https://www.ich.org/>

News/Pubs/Press Releases [Selective]

[Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.](#)

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Varying deadlines depending on regulatory authority

ICRC [to 29 June 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 29 June 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

[EU Youth Empowerment Fund through the Global Youth Mobilization launch 'Open Call' to empower young people to drive the SDG Agenda](#)

27/06/2024 | Press release

Institut Pasteur [to 29 June 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified....

ISC / International Science Council [to 29 June 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 29 June 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 29 June 2024]

<http://www.ivi.int/>

IVI News & Announcements

[IVI, KDCA co-host '2024 Global Vaccine Forum' to accelerate development of vaccines for pandemic diseases](#)

June 27, 2024

[Kingdom of Thailand assumes Presidency of IVI's Global Council](#)

June 25, 2024

Johns Hopkins Center for Health Security [to 29 June 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 29 June 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Lebanon

Trapped in fear, Syrian refugees face unbearable choices in Lebanon

Project Update 28 Jun 2024

Myanmar

MSF suspends medical activities in northern Rakhine state, Myanmar

Project Update 27 Jun 2024

Access to medicines

MSF strengthening commitment to access to products for healthcare

Press Release 25 Jun 2024

National Academy of Medicine - USA [to 29 June 2024]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 29 June 2024]

<https://www.nationalacademies.org/newsroom?>

News

Register for June 26 State of the Science Address

Issues to be discussed include:

- U.S. global competitiveness in science and technology
- Alignment of U.S. research efforts with critical national priorities as public and private R&D funding shifts
- STEMM education to adequately prepare the next generation of leaders
- Public trust in science in an era of misinformation and disinformation

National Vaccine Program Office - U.S. HHS [to 29 June 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 29 June 2024]

<http://www.nih.gov/>

New Releases

No new digest content identified.

PATH [to 29 June 2024]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Sabin Vaccine Institute [to 29 June 2024]

<https://www.sabin.org/press/>
Latest News & Press Releases
No new digest content identified.

UNAIDS [to 29 June 2024]

<http://www.unaids.org/en>

News, Stories, Updates

Press release

Governments, civil society and United Nations agencies join together to “accelerate and sustain” a resilient response to HIV

GENEVA, 27 June 2024—At the 54th meeting of UNAIDS’ Programme Coordinating Board (PCB) which concluded today in Geneva, Switzerland, governments, civil society and United Nations agencies united in a shared commitment to accelerate progress to meet the 2025 AIDS targets and sustain the gains of the global HIV response toward 2030 and beyond...

UNICEF [to 29 June 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Remarks 27 June 2024

UNICEF Director of Emergency Operations, Lucia Elmi’s remarks on Sudan at the Daily Press Briefing by the Office of the Spokesperson for the Secretary-General

YORK, 27 June 2024 – "The widespread food insecurity that my colleagues at FAO and WFP have described has a particularly devastating effect on, and creates specific and distinctly chilling risks for Sudan’s children - boys and girls. "Our projections indicate that 3.7 million children will suffer from acute malnutrition this year, with over...

Press release 27 June 2024

Sudan is facing an unprecedented hunger catastrophe, say UN agency chiefs

ROME/NEW YORK, 27 June 2024 – Alarming new food security projections for Sudan published today show that Sudan is facing a devastating hunger catastrophe on a scale not seen since the Darfur crisis in the early 2000s, warn the heads of three United Nations agencies. The Food and Agriculture Organization of the United Nations (FAO), UN Children’s...

Unitaid [to 29 June 2024]

<https://unitaid.org/>

Featured News

27 June 2024

In an open letter, Unitaid urges MSF to continue its critical work in advancing access for key health products

27 June 2024

Global Fund and Unitaid Increase Collaboration to Advance Equitable Access to Health Products

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and Unitaid signed a new collaboration framework to advance equitable access to high-quality and affordable health products and innovations in low- and middle-income countries over the next three years.

Vaccine Equity Cooperative [nee Initiative] [to 29 June 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative (Sabin) [to 29 June 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 29 June 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 29 June 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

June 2024: Vaccines and Infectious Diseases in the News

Published on Jun 12, 2024

Wellcome Trust [to 29 June 2024]

<https://wellcome.org/>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 29 June 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

Wistar’s Dr. Noam Auslander Awarded \$600K V Foundation Grant to Identify Connections between Gut Microbial Genes & Melanoma Immunotherapy

PHILADELPHIA — (Thursday, June 27, 2024) — The Wistar Institute’s Noam Auslander, Ph.D., assistant professor in the Molecular and Cellular Oncogenesis Program at the Ellen and Ronald Caplan Cancer ...

World Bank [to 29 June 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 29 June 2024]

<https://www.wfpha.org/>

Blog, Event

Webinar: Enhancing Vaccination Data Collection for Healthcare Workers in LICs and LMICs

Jun 28, 2024

Webinar: Enhancing Vaccination Data Collection for Healthcare Workers in LICs and LMICs Date: 26th June 2024 | 10:00 - 11:00 CEST This webinar addresses the critical need to gather comprehensive vaccination data on healthcare workers in low-income...

World Medical Association [WMA] [to 29 June 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [OIE] [to 29 June 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....
.....

ARM [Alliance for Regenerative Medicine] [to 29 June 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 29 June 2024]

<https://www.bio.org/press-releases>

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 29 June 2024]

<http://www.dcvmn.org/>

News; Upcoming events

ANNUAL GENERAL MEETING 2024

October 16 - 18, 2024 São Paulo, Brazil

ICBA – International Council of Biotechnology Associations [to 29 June 2024]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [to 29 June 2024]

<https://ifpma.org/>

News, Statements [Selected]

No new digest announcements identified.

International Alliance of Patients' Organizations – IAPO [to 29 June 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 29 June 2024]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News

June 28, 2024

[Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa](#)

:: Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccine

:: Emergency Use Authorization for the MVA-BN vaccine has been issued in the DR Congo

June 26, 2024

[Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA](#)

Bharat Biotech

Press Releases - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - - No new digest announcements identified

Biological E

News - No new digest announcements identified

BioNTech

Press Releases

27 June 2024

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

:: The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older

:: Recommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineages

:: Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

26 June 2024

Statement: US Centers for Disease Control and Prevention's Advisory Committee on Immunisation Practices updates recommendations on adult RSV vaccines ahead of the next season

GSK today announced that the US CDC ACIP voted in favour of recommending the routine use of RSV vaccines in all adults aged 75 and above.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified.

Merck

News releases

[CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE™ \(Pneumococcal 21-valent Conjugate Vaccine\) for Pneumococcal Vaccination in Appropriate Adults](#)

June 27, 2024

[USDA Approves Merck Animal Health's NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza](#)

June 25, 2024

Moderna

Press Releases

June 28, 2024

[EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna's RSV Vaccine, mRESVIA\(R\)](#)

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Jun 27, 2024

Statement COVID-19

[U.S. CDC & ACIP Recommend Use of Authorized and Approved 2024-2025 COVID-19 Vaccines](#)

Jun 24, 2024 COVID-19

[Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine](#)

Pfizer

Recent Press Releases

06.27.2024

[Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union](#)

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

SK Biosciences

Press Releases

SK bioscience Acquires Global Biotech IDT Biologika

2024.06.27

-The company secures management control of IDT Biologika, a global CDMO company with state-of-the-art manufacturing facilities in Germany.

-SK bioscience will secure business capabilities of IDT Biologika, maintaining long-standing partnerships with leading global pharma companies and institutions, such as Takeda, German Government and CEPI.

-The deal represents an initial leap forward into global markets with significant improvements in production infrastructures and securing key personnel.

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases

June 24, 2024

Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ®

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....

.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

.....

.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

ELSIcon Special Issue

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 6: E435-505 June 2024

<https://journalofethics.ama-assn.org/issue/antimicrobial-stewardship>

Antimicrobial Resistance

Microbes include bacteria, parasites, viruses, and fungi that constantly evolve. Antimicrobial resistance (AMR) happens when microbes change, becoming harder to treat in individual human and nonhuman animals and plants with antibiotic, antiparasitic, antiviral, and antifungal agents. Resistant pathogens are easily transmissible across human and nonhuman ecology, and this theme issue attends to ethical, clinical, and policy dimensions of this set of problems. National and international burden of AMR has been assessed in terms of infection incidence, deaths, hospital length of stay, and location-specific costs of developing and applying specific pathogen-drug combinations to try to save lives and preserve food supplies. Routine and focused surveillance is key to understanding microbiological, individual, social, and ecological root causes, downstream effects, and sources of domestic and global inequity in AMR.

American Journal of Human Genetics

Jun 06, 2024 Volume 111 Issue 6 p997-1240

<https://www.cell.com/ajhg/current>

This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

In recent years, polygenic risk scores (PRSs) have evolved from a statistical metric into a tool poised for introduction into clinical use. Yet, for all the promise presented by PRSs, researchers from multiple fields have highlighted several areas of concern that need to be considered before PRSs are fully integrated into standard of care. Chief among these are scientific and ethical matters related to the differential performance of PRSs across groups of humans. In this issue, Lewis et al. discuss how the eMERGE Network approached these challenges in a clinical trial that returned PRSs for ten conditions to over 25,000 US-based participants.

American Journal of Infection Control

June 2024 Volume 52 Issue 6 p625-744

<http://www.ajicjournal.org/current>
[Reviewed earlier]

American Journal of Preventive Medicine

June 2024 Volume 66 Issue 6 p927-1106

<https://www.ajpmonline.org/current>
[Reviewed earlier]

American Journal of Public Health

July 2024 114(7)

<http://ajph.aphapublications.org/toc/ajph/current>
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 6 (Jun 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/4/tpmd.110.issue-6.xml>
[Reviewed earlier]

Annals of Internal Medicine

Volume 331 June 2024

<https://www.acpjournals.org/toc/aim/current>
[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 330 June 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/330/suppl/C>
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 29 June 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 29 June 2024)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 29 June 2024)

[Duration of effectiveness of the COVID-19 vaccine in Japan: a retrospective cohort study using large-scale population-based registry data](#)

Most evidence of the waning of vaccine effectiveness is limited to a relatively short period after vaccination.

Authors: Kohei Uemura, Sachiko Ono, Nobuaki Michihata, Hayato Yamana and Hideo Yasunaga

Citation: BMC Infectious Diseases 2024 24:648

Content type: Research Published on: 28 June 2024

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 29 June 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 29 June 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 29 June 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 29 June 2024)

[Availability of published evidence on coverage, cost components, and funding support for digitalisation of infectious disease surveillance in Africa, 2003–2022: a systematic review](#)

The implementation of digital disease surveillance systems at national levels in Africa have been challenged by many factors. These include user applicability, utility of IT features but also stable financial ...

Authors: Basil Benduri Kaburi, Manuela Harries, Anja M. Hauri, Ernest Kenu, Kaspar Wyss, Bernard Chawo Silenou, Carolina J Klett-Tammen, Cordula Ressing, Jannis Awolin, Berit Lange and Gérard Krause

Citation: BMC Public Health 2024 24:1731

Content type: Research Published on: 28 June 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 29 June 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

June 2024 - Volume 29 - 3

<https://ebm.bmj.com/content/29/3>

[Reviewed earlier]

BMJ Global Health

May 2024 - Volume 9 - Suppl 2

https://gh.bmj.com/content/9/Suppl_2

Learning from success: the maternal and newborn health transition in exemplar countries

[Reviewed earlier]

Bulletin of the Atomic Scientists

May 2024

<https://thebulletin.org/magazine/2024-05/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(6); 2024 Jun 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/463492/>

[Reviewed earlier]

Cell

Jun 06, 2024 Volume 187 Issue 12 p2897-3162

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 50, Issue 4 July 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 6 Pages: 1177-1459 June 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Moving the Needle for Oncology Dose Optimization

[Reviewed earlier]

Clinical Therapeutics

May 2024 Volume 46 Issue 5 p381-440

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 21 Issue 3, June 2024

<https://journals.sagepub.com/toc/ctja/21/3>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 29 June 2024]
[No new digest content identified]

Contemporary Clinical Trials

Volume 141 June 2024
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/141/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 3 / June 2024
<https://www.liebertpub.com/toc/crispr/7/3>
Editorial Free
[Surveying the State of CRISPR and Gene Editing](#)
[Rodolphe Barrangou](#)
Pages:133–134
Published Online:21 June 2024
<https://doi.org/10.1089/crispr.2024.0045>

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023
<https://link.springer.com/journal/40142/volumes-and-issues/11-3>
[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 5 2024
<https://www.tandfonline.com/toc/icmo20/current>
[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2024 - Volume 37 - Issue 4
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>
NOSOCOMIAL AND HEALTHCARE RELATED INFECTIONS
[Navigating the future: machine learning's role in revolutionizing antimicrobial stewardship and infection prevention and control](#)
Hanna, John J.; Medford, Richard J.
Current Opinion in Infectious Diseases. 37(4):290-295, August 2024.

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 29 June 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 2 Pages: 49-134 June 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 34, Issue 3, 2024

<https://www.tandfonline.com/toc/cdip20/34/3>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue S1 June 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

Introduction to Special Issue Open Access

[Foresight and futures thinking for international development co-operation: Promises and pitfalls](#)

Fraser Reilly-King, Colleen Duggan, Alex Wilner

First Published: 12 June 2024

Abstract

Motivation

Strategic foresight is gaining traction for anticipating changes in a volatile, uncertain, complex, and ambiguous (VUCA) world—one which will require different mindsets and approaches. Yet international development co-operation practitioners have been slow to adopt foresight.

Purpose

What promises and pitfalls should development practitioners consider in order to integrate strategic foresight into their work?

Methods and approach

We review the literature on strategic foresight applied to development. We draw on reflections from the articles included in this special issue. We incorporate the International Development Research Centre's experiences and early insights on the use of foresight for development.

Findings

Strategic foresight provides tools to anticipate long-term and potentially disruptive change. To apply the approach effectively, organizations need to understand the debates about foresight. But no one size fits all: organizations must identify where and how foresight can best be used; be clear on its purpose, use, and end-users; be sensitive to how foresight intersects with broader calls for decolonizing development and the future; and should adapt methods to different sociocultural contexts. Connecting foresight practitioners and international development actors to explore potential synergies between these two worlds offers opportunities to innovate.

Policy implications

Traditional, short-term strategic planning, and reactive responses to emerging crises, are increasingly ill-suited to a VUCA world. To be fit for the future, international development actors must consider adding proactive longer-term anticipatory planning—that accommodates more systematic understanding and appreciation of plausible futures—to reactive responses.

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 3 July 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/3>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 6 12 June 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 7—July 2024

<http://wwwnc.cdc.gov/eid/>

Synopses

[Looking Beyond the Lens of Crimean-Congo Hemorrhagic Fever in Africa](#) [PDF - 875 KB - 7 pages]

O. Okesanya et al.

[Strategies to Enhance COVID-19 Vaccine Uptake among Prioritized Groups, Uganda—Lessons Learned and Recommendations for Future Pandemics](#) [PDF - 1.17 MB - 9 pages]

D. Kiiza et al.

Epidemics

Volume 47 June 2024

<https://www.sciencedirect.com/journal/epidemics/vol/47/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 3 Pages: 1-39 May–June 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

Children and human challenge studies Challenges for research with migrants

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 3, June 2024

<https://academic.oup.com/eurpub/issue/34/3>

Migration and Health

Editor's Choice

[**Barriers and drivers to COVID-19 vaccination among the migrant and non-migrant population in Germany, 2021**](#)

Elisa Wulkotte and others

European Journal of Public Health, Volume 34, Issue 3, June 2024, Pages 530–536,

<https://doi.org/10.1093/eurpub/ckae017>

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

May/June 2024 Volume 103, Number 3

<https://www.foreignaffairs.com/issues/2023/103/3>

[Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 6 June 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/6>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 29 June 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 3 June 27, 2024

<http://www.ghspjournal.org/content/current>

PROGRAM CASE STUDIES

Acceptability of an Incentivized Peer Referral Intervention to Address COVID-19 Vaccine Hesitancy Among Adults in Yopougon-Est, Côte d'Ivoire

Katherine Thanel, Brian Pedersen, Yao Kouakou Albert, Mariame Louise Ouattara, Dorgeles Gbeke, Virupax Ranebennur and Holly M. Burke

Global Health: Science and Practice June 2024, 12(3):e2300468; <https://doi.org/10.9745/GHSP-D-23-00468>

A pilot intervention in Yopougon-Est, Côte d'Ivoire, found incentivizing recent COVID-19 vaccine recipients to refer peers for vaccination using paper coupons acceptable.

Accelerating COVID-19 Vaccination Among People Living With HIV and Health Care Workers in Tanzania: A Case Study

Mohamed F. Jalloh, Florian Tinuga, Mohamed Dahoma, Anath Rwebembera, Ntuli A. Kapologwe, Daniel Magesa, Kokuhabwa Mukurasi, Oscar Ernest Rwabiyago, Jaiving Kazitanga, Angela Miller, David Sando, Haruka Maruyama, Redempta Mbatia, Florence Temu, Eva Matiko, Kokuhumbya Kazaura, Prosper Njau, Jennifer Imaa, Tara Pinto, Sophia A. Nur, Nicolas Schaad, Augustine Malero, Damian Damian, Jonathan Grund, George S. Mgomella, Alison Johnson, Gbolahan Cole, Eunice Mmari, Wangeci Gatei and Mahesh Swaminathan

Global Health: Science and Practice June 2024, 12(3):e2300281; <https://doi.org/10.9745/GHSP-D-23-00281>

Within a 12-month period, targeted strategies increased COVID-19 vaccination uptake, minimized wastage of limited vaccine supply, and reduced missed opportunities for vaccination among people living with HIV and health care workers in Tanzania.

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 29 June 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)
<http://www.tandfonline.com/toc/rgph20/current>
[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>
[Accessed 29 June 2024]
[No new digest content identified]

Health and Human Rights

Volume 26, Issue 1, June 2024
<https://www.hhrjournal.org/volume-26-issue-1-june-2024/>
SPECIAL SECTION – COMMEMORATING 30 YEARS
[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 1 - January 2024
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 5, June 2024
<https://academic.oup.com/heapol/issue/39/5>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 29 June 2024]

[A health technology assessment of COVID-19 vaccination for Nigerian decision-makers: Identifying stakeholders and pathways to support evidence uptake](#)

Nigeria commenced rollout of vaccination for coronavirus disease 2019 (COVID-19) in March 2021 as part of the national public health response to the pandemic. Findings from appropriately contextualized cost–ef...

Authors: Benjamin S. C. Uzochukwu, Chinyere Okeke, Faisal Shuaib, Sergio Torres-Rueda, Anna Vassall, Mark Jit, Justice Nonvignon, Adaora C. Uzochukwu and Francis Ruiz

Citation: Health Research Policy and Systems 2024 22:73

Content type: Research Published on: 26 June 2024

Human Gene Therapy

Volume 35, Issue 11-12 / June 2024
<https://www.liebertpub.com/toc/hum/35/11-12>
Review

[A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies](#)

Sumaya Abuloha, Shu Niu, Darlene Adirika, Benjamin P. Harvey, and Mikael Svensson

Pages:365–373

Published Online:9 April 2024

<https://doi.org/10.1089/hum.2023.186>

Abstract

Cell and gene therapy (CGT) innovations have provided several significant breakthroughs in recent years. However, CGTs often come with a high upfront cost, raising questions about patient access, affordability, and long-term value. This study reviewed cost-effectiveness analysis (CEA) studies that have attempted to assess the long-term value of Food and Drug Administration (FDA)-approved CGTs. Two reviewers independently searched the Tufts Medical Center CEA Registry to identify all studies for FDA-approved CGTs, per January 2023. A data extraction template was used to summarize the evidence in terms of the incremental cost-effectiveness ratio expressed as the cost per quality-adjusted life year (QALY) and essential modeling assumptions, combined with a template to extract the adherence to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. The review identified 26 CEA studies for seven CGTs. Around half of the base-case cost-effectiveness results indicated that the cost per QALY was below \$100,000-\$150,000, often used as a threshold for reasonable cost-effectiveness in the United States. However, the results varied substantially across studies for the same treatment, ranging from being considered very cost-effective to far from cost-effective. Most models were based on data from single-arm trials with relatively short follow-ups, and different long-term extrapolations between studies caused large differences in the modeled cost-effectiveness results. In sum, this review showed that, despite the high upfront costs, many CGTs have cost-effectiveness evidence that can support long-term value. Nonetheless, substantial uncertainty regarding long-term value exists because so much of the modeling results are driven by uncertain extrapolations beyond the clinical trial data.

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024

<https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Jun 11, 2024 Volume 57 Issue 6 p1177-1442

<https://www.cell.com/immunity/current>

Featured Article

[AI and immunology](#)

Ronald N. Germain, et al.

AI is rapidly becoming part of many aspects of daily life, with an impact that reaches all fields of research. We asked investigators to share their thoughts on how AI is changing immunology research, what is necessary to move forward, the potential and the pitfalls, and what will remain unchanged as the field journeys into a new era.

Perspective

Challenges and opportunities in long COVID research

Rebecca E. Hamlin, Catherine A. Blish

Long COVID (LC) has become a major public health concern, necessitating multi-pronged research efforts to understand the pathophysiologic mechanisms of this condition and aid in patient diagnosis and treatment. In this perspective, Hamlin and Blish review previous and ongoing studies, highlighting the challenges and opportunities in LC research.

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 29 June 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 29 June 2024]

[No new digest content identified]

International Health

Volume 16, Issue 3, May 2024

<https://academic.oup.com/inthealth/issue/16/3>

[Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 1 (Jun 2024):

<https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml>

Special Issue on Inter-State Communications

Table of Contents

[New issue; No digest content identified]

International Journal of Community Medicine and Public Health

Vol. 11 No. 7 (2024): July 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/114>

[New issue; No digest content identified]

International Journal of Epidemiology

Volume 53, Issue 3, June 2024

<https://academic.oup.com/ije/issue/53/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

Table of contents

[Reviewed earlier]

JAMA

June 25, 2024, Vol 331, No. 24, Pages 2063-2142

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

JAMA Health Forum

June 2024, Vol 5, No. 6

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

June 2024, Vol 178, No. 6, Pages 515-632

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBİ Evidence Synthesis

June 2024 - Volume 22 - Issue 6

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

Editorial

[Unlocking the power of global collaboration: building a stronger evidence ecosystem together](#)

Jordan, Zoe; Welch, Vivian; Soares-Weiser, Karla

JBİ Evidence Synthesis. 22(6):947-948, June 2024.

Journal of Adolescent Health

June 2024 Volume 74 Issue 6 p1057-1270

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 3 June 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-3>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[Reviewed earlier]

Journal of Development Economics

Volume 169 June 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/169/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 1-2, February–April 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

June 2024 - Volume 78 - 6

<https://jech.bmj.com/content/78/6>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 2 Pages: 237-467 June 2024

<https://onlinelibrary.wiley.com/toc/17565391/current>

Letters

[COVID-19 vaccine hesitancy and uptake among adults living with HIV in the eastern coast of Tanzania: A nested cross-sectional study](#)

Goodluck G. Nyondo, Fredrick K. Msalenge, Frank A. Majaliwa, Erca Deogratias, Erick Philipo, Belinda J. Njiro, Emmanuel Mang'ombe, David T. Myemba, George M. Bwire

Pages: 247-252

First Published: 06 May 2024

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 2, May 2024

<https://muse.jhu.edu/issue/52595>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 3 June 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 229, Issue 5, 15 May 2024

<https://academic.oup.com/jid/issue/229/5>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 4 Pages: 3-2228 May 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

June 2024 - Volume 50 - 6

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 1 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 269 June 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/269/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

May/June 2024 - Volume 30 - Issue 3

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 1, March 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-1>

[Reviewed earlier]

Journal of the Royal Society – Interface

June 2024 Volume 21 Issue 215

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 4, May 2024

[Reviewed earlier]

Journal of Virology

Volume 98 • Number 6 • June 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jun 29, 2024 Volume 403 Number 10446 p2755-2836

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

[The updated International Health Regulations: good news for global health equity](#)

Ashley Bloomfield, Abdullah Ass

The Lancet Child & Adolescent Health

July 2024 Volume 8 Number 7 p467-544

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Jul 2024 Volume 6 Number 7 e433-e535

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Jul 2024 Volume 12 Number 7 e1068-e1213
<https://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

Jul 2024 Volume 24 Number 7 p665-792, e416-e472
<https://www.thelancet.com/journals/laninf/issue/current>
Articles

[Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial](#)

Avika Dixit, et al.

[Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021](#)

GBD 2021 Tuberculosis Collaborators

[Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study](#)

Michelle Ylade, et al.

[Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial](#)

Ynke Larivière, et al.

[Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial](#)

Jeannot F Zinsou, et al.

Lancet Public Health

Jun 2024 Volume 9 Number 6 e345-e410
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Jul 2024 Volume 12 Number 7 p499-574, e42
<https://www.thelancet.com/journals/lanres/issue/current>
Editorial

[Respiratory syncytial virus vaccines: the future is bright](#)

The Lancet Respiratory Medicine

Personal View

[Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally](#)

Anne B Chang, et al.

Summary

Indigenous peoples around the world bear a disproportionate burden of chronic respiratory diseases, which are associated with increased risks of morbidity and mortality. Despite the imperative to address global inequity, research focused on strengthening respiratory health in Indigenous peoples is lacking, particularly in low-income and middle-income countries. Drivers of the increased rates and severity of chronic respiratory diseases in Indigenous peoples include a high prevalence of risk factors (eg, prematurity, low birthweight, poor nutrition, air pollution, high burden of infections, and poverty) and poor access to appropriate diagnosis and care, which might be linked to colonisation and historical and current systemic racism. Efforts to tackle this disproportionate burden of chronic respiratory diseases must include both global approaches to address contributing factors, including decolonisation of health care and research, and local approaches, co-designed with Indigenous people, to ensure the provision of culturally strengthened care with more equitable prioritisation of resources. Here, we review evidence on the burden of chronic respiratory diseases in Indigenous peoples globally, summarise factors that underlie health disparities between Indigenous and non-Indigenous people, propose a framework of approaches to improve the respiratory health of Indigenous peoples, and outline future directions for clinical care and research.

Maternal and Child Health Journal

Volume 28, Issue 5 May 2024

<https://link.springer.com/journal/10995/volumes-and-issues/28-5>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 4, May 2024

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 102, Issue 2 Pages: 271-516 June 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Jun 05, 2024 Volume 32 Issue 6 p1597-2036

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 630 Issue 8018, 27 June 2024

<https://www.nature.com/nature/volumes/630/issues/8018>

Editorial 26 Jun 2024

[**Is science's dominant funding model broken?**](#)

Should one principal investigator have the power to determine postdocs' careers? Share your thoughts on academia's dominant funding model in our survey and reader poll.

Article Open Access 05 Jun 2024

[Scaling neural machine translation to 200 languages](#)

Scaling neural machine translation to 200 languages is achieved by No Language Left Behind, a single massively multilingual model that leverages transfer learning across languages.

Marta R. Costa-jussà, James Cross, Jeff Wang

Nature Biotechnology

Volume 42 Issue 6, June 2024

<https://www.nature.com/nbt/volumes/42/issues/6>

Editorial 06 Jun 2024

[Cis-editing for all](#)

CRISPR technologies offer new opportunities to democratize gene-edited crops and promote global sustainability.

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 29 June 2024)

[No new digest content identified]

Nature Genetics

Volume 56 Issue 6, June 2024

<https://www.nature.com/ng/volumes/56/issues/6>

[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 6, June 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/6>

[New issue; No digest content identified]

Nature Medicine

Volume 30 Issue 6, June 2024

<https://www.nature.com/nm/volumes/30/issues/6>

Editorial 10 June 2024

[To respond to the threat of avian influenza, look back at lessons learned from COVID-19](#)

Tackling an avian influenza virus strain with pandemic potential should be straightforward — if lessons from the COVID-19 pandemic are heeded.

Nature Reviews Drug Discovery

Volume 23 Issue 6, June 2024

<https://www.nature.com/nrd/volumes/23/issues/6>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 6, June 2024

<https://www.nature.com/nrg/volumes/25/issues/6>

[Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 6, June 2024

<https://www.nature.com/nri/volumes/24/issues/6>

World View 24 Apr 2024

[Harnessing our lived experience for science communication](#)

Adrian Liston, professor of pathology at the University of Cambridge, UK, has published several illustrated children's books on the topic of vaccination and has developed a computer game called 'VirusFighter'. Here, he shares his thoughts on how to become an effective science communicator.
Adrian Liston

New England Journal of Medicine

Volume 390 No. 24 June 27, 2024

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 3 No. 6 June 2024

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 29 June 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 6 June 2024

<https://publications.aap.org/pediatrics/issue/153/6>

[Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 6 June 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-6>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 29 June 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 29 June 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSglobalPublicHealth&q=&resultsPerPage=60

(Accessed 29 June 2024)

[Feasibility and acceptability of collecting dried blood spots \(DBS\) from children after vaccination during supplementary immunization activities to estimate measles and rubella seroprevalence](#)

Andrea C. Carcelen, Christine Prosperi, Mutinta Hamahuwa, Kelvin Kapungu, Gershom Chongwe, Francis D. Mwansa, Phillimon Ndubani, Edgar Simulundu, Innocent C. Bwalya, Kalumbu H. Matakala, Gloria Musukwa, Irene Mutale, Evans Betha, Nchimunya Chaavwa, Lombe Kampamba, Japhet Matoba, Passwell Munachoonga, Webster Mufwambi, Ken Situtu, Philip E. Thuma, Constance Sakala, Princess Kayeye, Shaun A. Truelove, Amy K. Winter, Matthew J. Ferrari, William J. Moss, Simon Mutembo

Research Article | published 28 Jun 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002985>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 29 June 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 29 June 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 29 June 2024]

[Challenges of biomedical research collaboration in India: Perceptions of Indian and international researchers](#)

Vaishali Deshmukh, Tanuja Agarwala, Archisman Mohapatra, Sanjiv Kumar, Sushma Acquilla, Manoj K. Das, Rajib Dasgupta, Sanjay Chaturvedi, Subrata Sinha, Sharmila Mukherjee, Mubashir Angolkar, Naveet Wig, Navneet K. Dhamija, Narendra Kumar Arora, on behalf of the INCLEN Leadership Study Group

Research Article | published 28 Jun 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0305159>

Cost-effective analysis of hepatitis A vaccination in Kerala state, India

Yogesh Krishnarao Gurav, Bhavani Shankara Bagepally, Natthakan Chitpim, Abhasnee Sobhonslidsuk, Mohan Digambar Gupte, Usa Chaikledkaew, Ammarin Thakkestian, Montarat Thavorncharoensap

Research Article | published 27 Jun 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0306293>

The implementation of a new measles vaccine mandate in Germany: A qualitative study in local health departments

Sophia Werdin, Julia Neufeind

Research Article | published 25 Jun 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0306003>

COVID-19 vaccine acceptance and hesitancy in Ghana: A systematic review

Godwin Banafo Akrong, Rosemond Akpene Hiadzi, Antonia Bernadette Donkor, Daniel Kwasi Anafo

Research Article | published 25 Jun 2024 PLOS ONE
<https://doi.org/10.1371/journal.pone.0305993>

PLOS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 29 June 2024]

A new landscape for malaria vaccine development

Alexander J. Laurenson, Matthew B. Laurens

Pearls | published 27 Jun 2024 PLOS Pathogens
<https://doi.org/10.1371/journal.ppat.1012309>

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruses

Amy Flaxman, Sarah Sebastian, Sofia Appelberg, Kuan M. Cha, Marta Ulaszewska, Jyothi Purushotham, Ciaran Gilbride, Hannah Sharpe, Alexandra J. Spencer, Sagida Bibi, Daniel Wright, Isabel Schmidt, Stuart Dowall, Linda Easterbrook, Stephen Findlay-Wilson, Sarah Gilbert, Ali Mirazimi, Teresa Lambe

Research Article | published 26 Jun 2024 PLOS Pathogens
<https://doi.org/10.1371/journal.ppat.1012262>

PNAS - Proceedings of the National Academy of Sciences of the United States

June 25, 2024 vol. 121 no. 26

<https://www.pnas.org/toc/pnas/121/25>

Economic Sciences

Research Article June 17, 2024 Coronavirus (COVID-19)

The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic

In response to the COVID-19 pandemic, governments directly funded vaccine research and development (R&D), quickly leading to multiple effective vaccines and resulting in enormous health and economic benefits to society. We develop a simple economic model ...

Daniel Tortorice, Rino Rappuoli and David E. Bloom

PNAS Nexus

Volume 3, Issue 5, May 2024

<https://academic.oup.com/pnasnexus/issue/3/5>

[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 2 - April 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 183 June 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/183/suppl/C>

[New issue; No digest content identified]

Proceedings of the Royal Society B

June 2024 Volume 291 Issue 2025

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 230 Pages e1-e6, 1-232 (May 2024)

<https://www.sciencedirect.com/journal/public-health/vol/230/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 3, May/June 2024

<https://journals.sagepub.com/toc/phrg/139/3>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 7, June 2024
<https://journals.sagepub.com/toc/QHR/current>
[New issue; No digest content identified]

Research Ethics

Volume 20 Issue 2, April 2024
<http://journals.sagepub.com/toc/reab/current>
Special collection: Research Integrity and Research Misconduct
[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>
[Accessed 29 June 2024]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>
Latest Articles
[No new digest content identified]

Risk Analysis

Volume 44, Issue 6 Pages: 1269-1534 June 2024
<https://onlinelibrary.wiley.com/toc/15396924/current>
[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>
[Accessed 29 June 2024]
[Reviewed earlier]

Science

Volume 384| Issue 6703| 28 Jun 2024
<https://www.science.org/toc/science/current>
Policy Forum
[Unlock the potential of vaccines in food-producing animals](#)

BY Ramanan Laxminarayan, et al.
27 Jun 2024: 1409-1411

Broader coverage can have economic, climate-related, animal welfare, and human health benefits
Abstract

Animal vaccines help maintain healthy livestock and poultry populations, improve food safety, and reduce the transmission of zoonotic disease to humans ([1](#)). Such vaccines can reduce the clinical impact of pathogens on an individual animal, an important ethical consideration for improving animal welfare. However, the extent of routine vaccination among food-producing animals in low- and middle-

income countries (LMICs) is low and considerably lags vaccination rates in high-income countries (HICs) (see fig. S1). Many of the existing gaps in the area of vaccine development and deployment for terrestrial food-producing animals could be hugely aided by changes in policy and increases in funding. But this is also a scientific problem of fundamental importance and applied relevance. Improvement could simultaneously help mitigate climate change and pandemic risk, tackle antimicrobial resistance, and fight poverty. Few global investments could claim to have similarly broad benefits at so modest a cost.

Science and Engineering Ethics

Volume 30, Issue 3 June 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-3>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 753| 26 Jun 2024

<https://www.science.org/toc/stm/current>

Viewpoint

New government drug repurposing programs: Opportunities and uncertainties

BY Johnathon Liddicoat, et al.

26 Jun 2024

New government drug repurposing programs in the United States and Europe present new opportunities for stakeholders.

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 29 June 2024]

[No new digest content identified]

Social Science & Medicine

Volume 349 May 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/349/suppl/C>

[New issue; No digest content identified]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 29 June 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 2 April 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-2>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 59 May–June 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/59/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 6 Pages: i-iv, 447-540 June 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 18 Pages 3751-3930 (11 July 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/18>

Selected Content

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 29 June 2024]

Open Access Article

[Understanding the Reasons for Receiving HPV Vaccination among Eligible Adults in Italy](#)

by Grazia Miraglia del Giudice, Vincenza Sansone, Giorgia Della Polla and Italo Francesco Angelillo

Vaccines 2024, 12(7), 728; <https://doi.org/10.3390/vaccines12070728> (registering DOI) - 29 Jun 2024

Abstract

Background: This cross-sectional survey aimed to explore the reasons for receiving the HPV vaccination among eligible adults in Italy. Methods: The survey was conducted from July 2023 to April 2024 in Naples, Southern Italy. Results: A total of 282 questionnaires were collected. The [...]

Open Access Article

[Detection of Polioviruses Type 2 among Migrant Children Arriving to the Russian Federation from a Country with a Registered Poliomyelitis Outbreak](#)

by Olga E. Ivanova, Tatiana P. Ereemeeva, Olga Y. Baykova, Alexandr Y. Krasota, Elizaveta V.

Yakovchuk, Elena Y. Shustova, Lyudmila P. Malyshkina, Aida N.-I. Mustafina, Yulia M. Mikhailova, Alina

V. Chirova, Evgeniya A. Cherepanova, Nadezhda S. Morozova, Anna S. Gladkikh, Anna S. Dolgova,

Vladimir G. Dedkov, Areg A. Totolian and Liubov I. Kozlovskaya

Vaccines 2024, 12(7), 718; <https://doi.org/10.3390/vaccines12070718> - 28 Jun 2024

Abstract

The widespread use of the oral poliovaccine from Sabin strains (tOPV) radically reduced poliomyelitis incidence worldwide. However, OPV became a source of neurovirulent vaccine-derived polioviruses (VDPVs). Currently, circulating type 2 VDPVs (cVDPV2) are the leading cause of poliomyelitis. The novel OPV type 2 [...]

Open Access Article

[Timeliness of Childhood Vaccinations Following Strengthening of the Second Year of Life \(2YL\) Immunization Platform and Introduction of Catch-Up Vaccination Policy in Ghana](#)

by Pierre Muhoza, Monica P. Shah, Kwame Amponsa-Achiano, Hongjiang Gao, Pamela Quaye, William Opare, Charlotte Okae, Philip-Neri Aboyinga, Joseph Kwadwo Larbi Opare, Daniel C. Ehlman, Melissa T. Wardle and Aaron S. Wallace

Vaccines 2024, 12(7), 716; <https://doi.org/10.3390/vaccines12070716> - 27 Jun 2024

Abstract

Strengthening routine immunization systems to successfully deliver childhood vaccines during the second year of life (2YL) is critical for vaccine-preventable disease control. In Ghana, the 18-month visit provides opportunities to deliver the second dose of the measles–rubella vaccine (MR2) and for healthcare workers [...]

Open Access Article

[A Theory and Evidence-Based Artificial Intelligence-Driven Motivational Digital Assistant to Decrease Vaccine Hesitancy: Intervention Development and Validation](#)

by Yan Li, Kit-Ching Lee, Daniel Bressington, Qiuyan Liao, Mengting He, Ka-Kit Law, Angela Y. M. Leung, Alex Molassiotis and Mengqi Li

Vaccines 2024, 12(7), 708; <https://doi.org/10.3390/vaccines12070708> - 25 Jun 2024

Abstract

Vaccine hesitancy is one of the top ten threats to global health. Artificial intelligence-driven chatbots and motivational interviewing skills show promise in addressing vaccine hesitancy. This study aimed to develop and validate an artificial intelligence-driven motivational digital assistant in decreasing COVID-19 vaccine hesitancy [...]

Value in Health

June 2024 Volume 27 Issue 6 p687-820

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 178 June 2024

<https://www.sciencedirect.com/journal/world-development/vol/178/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 29 June 2024]
No new digest content identified.

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 29 June 2024]

[Filter: All articles]

Covid-19 vaccination decisions and impacts of vaccine mandates: A cross sectional survey of healthcare workers in Ontario, Canada

Claudia Chaufan, Natalie Hemsing, Rachael M

Herpes zoster vaccination and new diagnoses of dementia: A quasi-randomized study in Australia

Michael Pomirchy, Christian Bommer, Fabienne Pradella, Felix Michalik, Ruth Peters, Pascal Geldsetzer
medRxiv 2024.06.27.24309563; doi: <https://doi.org/10.1101/2024.06.27.24309563>

COVID-19 vaccination atlas: an integrative systems vaccinology approach

Wasim Aluísio Prates-Syed, Dennyson Leandro M Fonseca, Shahab Zaki Pour, Igor Salerno Filgueiras, Lena F Schimke, Aline Aparecida Lira, Nelson Cortes de Oliveira, Jaqueline Dinis Queiroz Silva, Evelyn Carvalho, Tania Geraldine Churasacari-Vinces, Lorena C S Chaves, Gerhard Wunderlich, Ricardo Durães-Carvalho, Niels O S Câmara, Haroldo Dutra Dias, Hans D Ochs, Jose E Krieger, Helder I Nakaya, Otavio Cabral-Marques, Gustavo Cabral-Miranda

medRxiv 2024.05.22.24307755; doi: <https://doi.org/10.1101/2024.05.22.24307755> Revision

Abstract

COVID-19 vaccinations have significantly controlled the pandemic. To elucidate their impact on the immune system, we developed a COVID-19 vaccination atlas through an integrative systems vaccinology approach. Our atlas includes both healthy individuals and those infected with or without prior vaccination, and covers the administration of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®, Spikevax®, and Comirnaty®. We identified critical markers to discriminate the various types of vaccines and infection, in which infection was associated with GATA3, ZNF3, KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1, LGALS3, and STAT5B. Additionally, we described the immunological signatures resulting from heterologous vaccination and infection, and also showed how a full vaccination regimen markedly limited the shift of immune responses during natural infection, thereby constraining disease progression. Finally, we described the common transcripts shared across COVID-19 vaccines and vaccines against other pathogens.

THE ECONOMIC BURDEN OF INVASIVE FORMS OF MENINGOCOCCAL INFECTION

Katsiaryna Serhiyenko, Irina Kozhanova, Oxana Romanova, Arthur Solodov, Polina Skutova
medRxiv 2024.06.25.24309375; doi: <https://doi.org/10.1101/2024.06.25.24309375>

High confidence and demand for hepatitis E vaccine during an outbreak in Bentiu, South Sudan: A qualitative study

Aybüke Koyuncu, Kinya Vincent Asilaza, John Rumunu, Joseph Wamala, Priscillah Gitahi, Zelig Antier, Jetske Duncker, Patrick Nkemenang, Primitivo Gakima, Melat Haile, Etienne Gignoux, Manuel Albela, Frederick Beden Loro, Duol Biem, Monica Rull, Andrew S Azman, Iza Ciglenecki, Robin Nesbitt
medRxiv 2024.06.25.24309497; doi: <https://doi.org/10.1101/2024.06.25.24309497>

Reshaping trade for vaccine equity: gaps in policy discourse

Toby Pepperrell, Meri Koivusalo, Liz Grant, Alison McCallum
medRxiv 2024.06.06.24308543; doi: <https://doi.org/10.1101/2024.06.06.24308543> Revision

Ethics in medical research: A quantitative analysis of the observations of Ethics Committees in research protocols

Santiago Vasco-Morales, Gabriel Alejandro Vasco-Toapanta, Cristhian Santiago Vasco-Toapanta, Paola Toapanta-Pinta

medRxiv 2024.06.23.24309373; doi: <https://doi.org/10.1101/2024.06.23.24309373>

Abstract

Objective To determine the frequency of observations made by Research Ethics Committees (RECs) regarding non-compliance with ethical principles in research.

Methods We searched for articles published up to November 30, 2023. In the databases: PubMed, Scopus and Google Scholar. Single-proportion meta-analyses were performed with the R V.3.6.1 program.

PROSPERO Registry CRD42021291893

Results 9 publications were reviewed, including cross-sectional, retrospective cohort, and descriptive studies. Lack of adherence to the ethical principle of justice was detected in up to 100% of the protocols evaluated. In addition, 9% (95% CI: 7-12) of observations in Latin America and 15% (95% CI: 9-24) in Europe. Autonomy was observed in 26% (95% CI: 20-33) of the protocols, reaching 17% (95% CI: 13-22) in experimental studies. Beneficence, lack of adherence in the protocols evaluated from 41.17% to 77.38%, observations per protocol ranged from 5.26% to 27.11%.

Discussion The findings highlighted disparities between regions and types of studies, reflecting cultural, interpretive, and human and institutional resource differences. RECs should ensure thorough and equitable assessments, promote fair selection, respect autonomy, and maximize benefits while minimizing risks to participants.

This study provides an assessment of ethical practices in medical research, highlighting key areas for improving compliance with fundamental ethical principles

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-No new digest content identified.]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 29 June 2024]

Selected Research

No new digest content identified.

* * * *

Think Tanks

Brookings [to 29 June 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 29 June 2024]

<https://www.cgdev.org/>

All Research [Selected]

No new digest content identified.

Chatham House [to 29 June 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [to 29 June 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 29 June 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 29 June 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 29 June 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 29 June 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 29 June 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

Feature Jun 24, 2024

[Public Trust in Government: 1958-2024](#)

Public trust in government remains low, as it has for much of the 21st century. Roughly two-in-ten Americans say they trust the government in Washington to do what is right “just about always” (2%) or “most of the time” (21%).

Rand [to 29 June 2024]
<https://www.rand.org/pubs.html>
Published Research [Selected]
No new digest content identified.

Urban Institute [to 29 June 2024]
<https://www.urban.org/publications>
New Research Publications - Selected

Fact Sheet
Accelerating Progress toward Health Care Equity: Insights from the Urban Institute’s Unequal Treatment at 20 Initiative
June 28, 2024

Fact Sheet
Promoting Equitable Development in Communities: An Overview of Five Promising Strategies
June 28, 2024

World Economic Forum [to 29 June 2024]
<https://agenda.weforum.org/press/>
Media [Selected]
New Report Charts Ethical AI Roadmap to Accelerate Social Innovation
News 25 Jun 2024

- A Schwab Foundation report shows how AI can accelerate innovation for impact, featuring 300 social innovators spearheading the adoption of the evolving technology
- Equity challenges are hindering progress – only 25% of women-led social enterprises are using AI, and data biases limit AI’s effectiveness in low- and middle-income countries
- To counter these and other barriers, the report presents a “PRISM” Framework to help social innovators and entrepreneurs navigate AI integration
- Read the report here

.....
.....

Public Consultations/Call for Inputs/Call for Papers

National Institutes of Health (NIH) Office of Science Policy (OSP): Request for Information on Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning

A Notice by the National Institutes of Health on 05/22/2024 **Comments Close: 07/22/2024**
SUMMARY:

The National Institutes of Health (NIH) is proposing to develop and implement a new policy within its Intramural Research Program (IRP) to promote access to products stemming from taxpayer-funded inventions. NIH seeks input on this draft policy and accompanying draft license agreement language that incorporates patient access in the commercialization process for NIH-owned inventions.

Supplemental Information

...NIH is proposing a new policy within the NIH IRP (see Appendix), to require that licensees that succeed in bringing certain products toward market submit a plan outlining steps they intend to take to promote patient access to those products. This new IRP policy makes it clear that access, defined broadly to include product affordability, availability, acceptability, and sustainability, is of paramount importance in providing a return on taxpayers' investment in biomedical research. This new policy would apply to patent licenses for the commercialization of drugs, biologics, vaccines, or devices. NIH would also employ a tiered approach, where licenses granted for late-stage inventions that are closer to market launch would include more specific, tailored access-oriented provisions, while licenses granted for early-stage inventions would be more flexible to reflect the higher uncertainty associated with technologies that lead to drugs, biologics, vaccines, or devices. Importantly, a final policy approach should be reasonable and not seek to force licensees into access obligations that obstruct commercial development or damage the viability and sustainability of a product in the market, while also balancing the need to promote access through reforms to various policies. The agency is proposing a flexible approach that allows appropriately tailored, commercially reasonable strategies to promote patient access across a range of technologies. This RFI is in relation to the licensing of government-owned inventions in accordance with 35 U.S.C. 207 and 37 CFR part 404....

Call for Public Comment: General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies that Utilize Real-World Data for Safety Assessment of Medicines.

ICH *Varying deadlines depending on regulatory authority*

The guideline will focus on non-interventional pharmacoepidemiological studies using Real-World Data (RWD) and will include basic principles that may apply to these studies when real-world data elements are included.

Guideline Draft:

https://database.ich.org/sites/default/files/ICH_M14_Step3_DraftGuideline_2024_0521.pdf

Public consultation dates [announced to date]:

MFDS, Republic of Korea - Deadline for comments by 15 July 2024

MHLW/PMDA, Japan - Deadline for comments by 28 July 2024

TFDA, Chinese Taipei - Deadline for comments by 30 September 2024

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*